Direkt zum Inhalt
Merck
Alle Fotos(1)

Key Documents

I0329000

Iopamidol

European Pharmacopoeia (EP) Reference Standard

Synonym(e):

(S)-N,N′-Bis-[2-hydroxy-1-(hydroxymethyl)-ethyl]-2,4,6-triiod-5-lactamidoisophthalamid

Anmeldenzur Ansicht organisationsspezifischer und vertraglich vereinbarter Preise
Alle Fotos(1)

About This Item

Empirische Formel (Hill-System):
C17H22I3N3O8
CAS-Nummer:
60166-93-0
Molekulargewicht:
777.09
UNSPSC-Code:
41116107
NACRES:
NA.24

Qualität

pharmaceutical primary standard

API-Familie

iopamidol

Hersteller/Markenname

EDQM

Anwendung(en)

pharmaceutical (small molecule)

Format

neat

Lagertemp.

2-8°C

InChI

1S/C17H22I3N3O8/c1-6(28)15(29)23-14-12(19)9(16(30)21-7(2-24)3-25)11(18)10(13(14)20)17(31)22-8(4-26)5-27/h6-8,24-28H,2-5H2,1H3,(H,21,30)(H,22,31)(H,23,29)/t6-/m0/s1

InChIKey

XQZXYNRDCRIARQ-LURJTMIESA-N

Suchen Sie nach ähnlichen Produkten? Aufrufen Leitfaden zum Produktvergleich

Verwandte Kategorien

Allgemeine Beschreibung

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Anwendung

Iopamidol EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Verpackung

Dieses Produkt wird, wie von der entsprechenden Pharmakopöe geliefert, angeboten. Die aktuellen Mengeneinheiten finden Sie im Referenzsubstanzen-Katalog der EDQM.

Sonstige Hinweise

Sales restrictions may apply.

Lagerklassenschlüssel

11 - Combustible Solids

WGK

WGK 1

Flammpunkt (°F)

Not applicable

Flammpunkt (°C)

Not applicable

Hier finden Sie alle aktuellen Versionen:

Analysenzertifikate (COA)

Lot/Batch Number

Leider sind derzeit keine COAs für dieses Produkt online verfügbar.

Wenn Sie Hilfe benötigen, wenden Sie sich bitte an Kundensupport

Besitzen Sie dieses Produkt bereits?

In der Dokumentenbibliothek finden Sie die Dokumentation zu den Produkten, die Sie kürzlich erworben haben.

Die Dokumentenbibliothek aufrufen

Akira Sato et al.
International journal of cardiology, 182, 419-425 (2015-01-18)
Coronary plaques with positive remodeling (PR) and low-attenuation plaques (LAP) by computed tomography angiography (CTA) might be associated with plaque vulnerability. The purpose of this study was to assess the relation between coronary plaques with PR and LAP by CTA
Nobuo Tomizawa et al.
International journal of cardiology, 176(3), 975-979 (2014-09-07)
The purpose was to investigate the diagnostic performance of coronary computed tomography angiography (CTA) when non-calcified uninterpretable segments were determined as either obstructive or patent. We also investigated the factors that could improve the diagnosis of CTA. A total of
Joseph B Muhlestein et al.
JAMA, 312(21), 2234-2243 (2014-11-18)
Coronary artery disease (CAD) is a major cause of cardiovascular morbidity and mortality in patients with diabetes mellitus, yet CAD often is asymptomatic prior to myocardial infarction (MI) and coronary death. To assess whether routine screening for CAD by coronary
Katsuya Miura et al.
International journal of cardiology, 181, 108-113 (2014-12-17)
The slow flow (SF) phenomenon is more prevalent in patients with acute coronary syndrome (ACS), who frequently exhibit vulnerable plaques in remote coronary arteries. We aimed to clarify the impact of nonculprit plaque characteristics on the occurrence of SF using
Yuzo Yamasaki et al.
European radiology, 24(12), 3289-3299 (2014-08-13)
To compare 256-slice cardiac computed tomography (CCT) with cardiac magnetic resonance (CMR) imaging to assess right ventricular (RV) function and pulmonary regurgitant fraction (PRF) in patients with repaired tetralogy of Fallot (TOF). Thirty-three consecutive patients with repaired TOF underwent retrospective
Alle zugehörigen Dokumente anzeigen

Unser Team von Wissenschaftlern verfügt über Erfahrung in allen Forschungsbereichen einschließlich Life Science, Materialwissenschaften, chemischer Synthese, Chromatographie, Analytik und vielen mehr..

Setzen Sie sich mit dem technischen Dienst in Verbindung.